Triple

T4771194
Position Surface form Disambiguated ID Type / Status
Subject Wegener's granulomatosis E105929 entity
Predicate treatedWith P2367 FINISHED
Object rituximab E46089 NE FINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: rituximab | Statement: [Wegener's granulomatosis, treatedWith, rituximab]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: rituximab
Context triple: [Wegener's granulomatosis, treatedWith, rituximab]
  • A. Rituxan chosen
    Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
  • B. Imbruvica
    Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
  • C. Tecentriq
    Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
  • D. Remicade
    Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
  • E. Actemra
    Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69bd43f226fc8190b867cc249c2a9042 completed March 20, 2026, 12:56 p.m.
NER Named-entity recognition batch_69bd655e5dcc8190a932be9b1baaffb2 completed March 20, 2026, 3:18 p.m.
NED1 Entity disambiguation (via context triple) batch_69be3a94e340819080fe92a2024abdaf completed March 21, 2026, 6:28 a.m.
Created at: March 20, 2026, 1:21 p.m.